LaNova Medicines Limited

Quick facts

Phase 3 pipeline

• LM-108 in combination with Toripalimab · Oncology
  LM-108 combined with Toripalimab works by blocking immune checkpoints to enhance anti-tumor immunity, with LM-108 targeting a specific immune pathway while Toripalimab blocks PD-1.
• Paclitaxel injection intravenous infusion · Oncology
  Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.

Phase 2 pipeline

• LM-108
• LM-24C5

Phase 1 pipeline

• LM-168
• LM-2417
• LM-299
• LM101

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• LaNova Medicines Limited portfolio CI brief
• LaNova Medicines Limited pipeline updates RSS